Meta-analysis: Colchicine reduces new cardiovascular events in patients with coronary artery disease
22 Jan, 2021 | 08:23h | UTCMeta-analysis Evaluating the Utility of Colchicine in Secondary Prevention of Coronary Artery Disease – The American Journal of Cardiology (link to abstract – $ for full-text)
Related randomized trials: Colchicine in patients with chronic coronary disease (study and commentaries) AND Low-Dose Colchicine Improves Outcomes after Myocardial Infarction (study and commentaries) AND Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) (study and commentary)
Commentary on Twitter
Meta-analysis Evaluating the Utility of Colchicine in Secondary Prevention of Coronary Artery Disease https://t.co/EbMATgpXn4
?Major adverse CV events 35%
?Risk of MI 27%
?Coronary revasc 39%
?Stroke 53% (0.47, CI 0.28-0.81)
?No impact on CV mortality@mencardio #colchicine— Lempira Guevara Matheus (@Lguevaramath) October 31, 2020